A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-12-31

Study Completion Date

2016-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous Ebola outbreaks have been limited to individual countries and contained by infection control activities. The current outbreak in West Africa is international, and air travel has resulted in a number of infected travellers crossing national borders. There are currently no specific treatments generally available for Ebola and the mortality is high, particularly in countries with limited intensive care facilities. There is currently no vaccine and the personal protection required by healthcare workers treating patients is cumbersome and requires full compliance to be protective.

There is now a consortium (VEBCON collaboration) of four clinical centres (in Kenya, Gabon, Switzerland and Germany), WHO and New Link Genetics (the vaccine manufacturer) under which this study will be conducted. The investigators are conducting this trial, a Phase I, open-label, dose escalation trial, designed to establish safety, tolerability and immunogenicity of two doses of VSVΔG-ZEBOV, an Ebola Virus Vaccine Candidate for the first time in sub-Saharan African populations.

The investigators plan to vaccinate 40 volunteers in Kenya. The trial will be conducted at the KEMRI-CGMR Coast site where healthcare workers (both clinical and laboratory) will be the primary target population as they are likely to be the recipients of a protective vaccine. The investigators will vaccinate a cohort of 20 volunteers at a low dose and then vaccinate a further cohort of 20 volunteers at full dose. Each volunteer will receive one dose of the vaccine. The investigators will follow them up for a period of one year looking to their safety and immunogenicity endpoints.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

VSV-ZEBOV Geneva Vaccine Trial

NCT02287480

Ebolavirus Disease

COMPLETED PHASE1/PHASE2

A Study in Tanzania of a New Vaccine Against Two Types of Ebola

NCT05301504

Ebola

UNKNOWN PHASE1

A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults

NCT02485301

Virus Diseases

COMPLETED PHASE2

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

NCT02509494

Ebola Virus Disease

COMPLETED PHASE3

A Study of a New Vaccine Against Two Types of Ebola

NCT05079750

Ebola

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is being conducted to assess safety and immunogenicity of an experimental ebola vaccine.

An outbreak due to the Ebola Zaire (ZEBOV) strain of unprecedented magnitude and scope and with a high mortality continues to spread across West Africa. No vaccine is currently licensed.

The specific opportunity at hand with rVSVΔG-ZEBOV-GP (BPSC1001) is to achieve long-lasting protective immunity to ZEBOV on a time scale of weeks in humans upon a single-shot vaccination, offering a discrete benefit over prime-boost vaccination protocols. The current outbreak represents a global health emergency and the need for access to therapeutic intervention and vaccines is paramount.

The vaccine investigated in this study might provide a critical tool to suppress future out-breaks of EVD in areas at risk.

This study is 1 of 4 clinical trials currently conducted as part of the WHO-led VEBCON consortium, aiming to generate harmonized data for the rVSVΔG-ZEBOV-GP (BPSC1001) vaccine candidate to allow optimized rapid decisions on dose and safety.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ebola Virus Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low dose arm

The low dose cohort will receive an intramuscular (deltoid) injection of 3x106 pfu of VSV-ZEBOV vaccine.

Group Type EXPERIMENTAL

VSV-ZEBOV

Intervention Type BIOLOGICAL

VSV-ZEBOV

Full dose arm

The full dose cohort will receive an intramuscular (deltoid) injection1x107 pfu of VSV-ZEBOV vaccine.

Group Type EXPERIMENTAL

VSV-ZEBOV

Intervention Type BIOLOGICAL

VSV-ZEBOV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VSV-ZEBOV

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

BSPSC1001

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Have provided written informed consent prior to screening procedures (i.e. participants must be literate).

* Healthy adult male or non-pregnant, non-lactating female, ages 18 to 55 (inclusive) at the time of screening
* Free of clinically significant health problems, as determined by pertinent medical history, clinical examination and blood tests at screening
* Available, able, and willing to participate for all study visits and procedures
* Negative pregnancy-test for female volunteers
* Females, of non-childbearing potential who are post-menopausal (i.e. ≥ one year without menses) or surgically sterilized (tubal ligation, bilateral oophorectomy, or hysterectomy)
* Females, of childbearing potential, who are willing to use effective methods of contraception for 14 days before vaccination and 30 days after vaccination.
* Males who are willing to use effective contraception following vaccination for a period of one week.
* Be willing to minimize blood and body fluid exposure of others for 5 days after vaccination

Exclusion Criteria

* • History of severe local or systemic reactions to any vaccination or a history of severe allergic reactions.

* Known allergy to the components of the BPSC1001 vaccine product
* Unable or unwilling to stay in the study area for the period of the study and comply with study procedures.
* Ongoing participation in another clinical trial
* Receipt of licensed vaccines within 14 days of planned study immunization (30 days for live vaccines)
* Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the investigator based on medical history, physical exam, and/or laboratory screening test
* Any serologic evidence of hepatitis B SAg or HIV infection.
* Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or uncontrolled diabetes
* Have an active malignancy or history of metastatic or hematologic malignancy
* Suspected or known alcohol and/or illicit drug abuse within the past 5 years
* Moderate or severe illness and/or fever \>38°C within 2 weeks prior to vaccination
* Pregnant or lactating woman or a woman who intends to become pregnant within 30 days following vaccination.
* Administration of immunoglobulins and/or any blood products within the 120 days preceding study entry or planned administration during the study period
* Administration of chronic (defined as more than 14 days) immunosuppressant's or other immune modifying drugs within 6 months of study entry
* Any other significant finding that in the opinion of the investigator would increase the risk of the individual having an adverse outcome from participating in this study

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes